projects underway


<a href='' rel='attachment wp-att-9438'><img class='alignnone size-full wp-image-9438' src='' alt='pittsburghuniversity' width='200' height='100' /></a><a href='' rel='attachment wp-att-9447'><img class='alignnone size-full wp-image-9447' src='' alt='boston' width='200' height='100' /></a><a href='' rel='attachment wp-att-9450'><img class='alignnone size-full wp-image-9450' src='' alt='choorts-for-heart' width='200' height='100' /></a><a href='' rel='attachment wp-att-9432'><img class='alignnone size-full wp-image-9432' src='' alt='toronto' width='200' height='100' /></a><a href='' rel='attachment wp-att-9456'><img class='alignnone size-full wp-image-9456' src='' alt='wadsworth' width='200' height='100' /></a><a href='' rel='attachment wp-att-9477'><img class='alignnone size-full wp-image-9477' src='' alt='gaain' width='200' height='100' /></a>
<a href='' rel='attachment wp-att-9474'><img class='alignnone size-full wp-image-9474' src='' alt='ibis' width='200' height='100' /></a><a href='' rel='attachment wp-att-9471'><img class='alignnone size-full wp-image-9471' src='' alt='upc' width='200' height='100' /></a><a href='' rel='attachment wp-att-9465'><img class='alignnone size-full wp-image-9465' src='' alt='grifols' width='200' height='100' /></a><a href='' rel='attachment wp-att-9453'><img class='alignnone size-full wp-image-9453' src='' alt='crg' width='200' height='100' /></a><a href='' rel='attachment wp-att-9444'><img class='alignnone size-full wp-image-9444' src='' alt='ciberned' width='200' height='100' /></a><a href='' rel='attachment wp-att-9441'><img class='alignnone size-full wp-image-9441' src='' alt='vallH' width='200' height='100' /></a><a href='' rel='attachment wp-att-9435'><img class='alignnone size-full wp-image-9435' src='' alt='malaga' width='200' height='100' /></a>
Phase III – Mild cognitive deterioration – plasmapheresis, plasma exchange with albumin and flebogamma – Recruiting (AMBAR)
Phase I – mild–moderate Alzheimer’s disease – active immunisation – Recruiting
Phase II/III – Mild–moderate Alzheimer’s disease – BACE1 inhibitor (beta-secretase) – Recruiting
Phase III – mild–moderate Alzheimer’s disease – TAU protein inhibitor – Recruiting
Phase II – Moderate–serious Alzheimer’s disease – behavioural disorder modulation – Recruiting
Phase I b – mild cognitive deterioration – BACE inhibitor (beta-secretase) – Recruiting

Phase III – Mild cognitive deterioration – Monoclonal antibody (Gantenerumab) – Recruiting closed (Scarlet)

Phase II – Moderate–serious Alzheimer’s disease – MAO-B (monoamine oxidase B) inhibitor – Recruiting closed (Mayflower)

Phase III (Open extension) – Mild–moderate Alzheimer’s disease – Monoclonal antibody (Solanezumab) – Recruiting closed
Phase II (Open extension) – Mild–moderate Alzheimer’s disease – Monoclonal antibody (Crenezumab) – Recruiting closed

Phase II b – Mild–moderate Alzheimer’s disease – Histamine H3 receptor antagonist – Recruiting closed



The Barcelona Alzheimer Treatment & Research Center is the fruit of collaboration between Fundació ACE and Grifols. It was designed to be an independent centre to promote and facilitate the diagnosis, treatment and biomedical research of Alzheimer’s and other neurodegenerative diseases which still can not be cured. We seek to consolidate the centre and its design as a point of reference for all Europe. Grifols drives the initiative, part of its global Alzheimer’s research strategy, through donations and a long-term collaboration agreement with Fundació ACE.

University of Pittsburgh

Fundació ACE and the University of Pittsburgh have been collaborating for over 15 years to predict, detect and treat Alzheimer’s disease and other dementias. One of the most visible projects of this important international collaboration is the biennial Barcelona – Pittsburgh Conference, which since 1998 has brought together the most distinguished researchers in the field of these neurodegenerative pathologies.

BANG (Barcelona Alzheimer Neuroimaging Group)

El grupo BANG es un proyecto de investigación para la investigación en neuroimagen y otras biomarcadores de las enfermedades neurodegenerativas, principalmente la Enfermedad de Alzheimer. Se establece como un grupo de referencia nacional e internacional para la promoción, la difusión y la investigación en nuevas terapias y metodologías relacionadas con enfermedades neuronales degenerativas.

The BANG group is a project of research investigating neuroimaging and other biomarkers of neurodegenerative disease, particularly of Alzheimer’s disease. The group is established as a national and international reference for the promotion, dissemination and research of new therapies and methodologies related to neuronal degenerative diseases.

One of its aims is the creation and validation of a multidisciplinary base including data on sociodemographics, cognition and neuropsychiatry, genetic samples, cerebrospinal fluid, biomarkers, PEIs and MRI and PET imaging. These data are to be used as predictors of Alzheimer’s and other related diseases in research activities. At the same time, BANG will promote translational research of neuronal degenerative diseases, directly benefiting affected people.

On 12 July 2012, a framework agreement on collaboration in research projects was signed for the formation of the group “BARCELONA ALZHEIMER NEUROIMATGE GRUPO – BANG”. Under the Foundation’s initiative, the group is made up of Fundació ACE. Institut Català de Neurociències Aplicades, Instituto de Investigación del Hospital de la Santa Creu y Sant Pau, Vall d’Hebrón Instituto de Investigación and Instituto Hospital del Mar de Investigaciones Médicas.

International Genomics of Alzheimer’s Project (IGAP)

Fundació ACE is also part of the International Genomics of Alzheimer’s Project (IGAP).

The IGAP project’s main objective is to understand the role of genetic heredity in the transmission of Alzheimer’s disease. Its research consists in drawing a map of all the genes that contribute to the progression of Alzheimer’s disease to identify the causes and the proteins involved. The IGAP genetic database has samples from more than 40,000 individuals, of whom half are healthy and the other half have Alzheimer’s disease.

A group of European and American scientists are collaborating in this international project, which is structured as four main consortia.

– The European Alzheimer’s Disease Initiative (EADI), led by Dr Philippe Amouyel of the Pasteur Institute in Lille and the University of Lille (France).

– The Alzheimer’s Disease Genetics Consortium (ADGC), led by Dr Gerard Schellenberg of the University of Pennsylvania School of Medicine (United States).

– The Genetic and Environmental Risk in Alzheimer’s Disease (GERAD) consortium, led by Dr Julie Williams of the University of Cardiff (United Kingdom).

– The neurology subgroup of Cohorts for Heart and Aging in Genomic Epidemiology (CHARGE), led by Dr Sudha Seshadri of the University of Boston (United States).

The findings of this research will contribute to the identification of new targets for drug development. However, IGAP’s conclusions will also be useful for taking predictive measures to determine which people are at greater risk of suffering this subtype of dementia.

CHARGE (Cohorts for Heart and Aging in Genomic Epidemiology)

The CHARGE (Cohorts for Heart and Aging in Genomic Epidemiology) consortium, directed by Dr Sudha Seshadri of the University of Boston, is one of the four genetic research groups which make up the IGAP project.

The CHARGE consortium, of which Fundació ACE is part, launched its activities in 2008. Its objective is to the facilitate meta-analysis and replication of genome-wide association studies, using the results of various classic population-based cohort studies such as the Framingham study, the Rotterdam Project or the Cardiovascular Health Study (among others).

Consorcio Español de Genética de Demencias (DEGESCO)

Fundació ACE promoted the creation of the Consorcio Español de Genética de Demencias (DEGESCO) in collaboration with 11 more groups belonging to CIBERNED (Centros de Investigación Biomédica en Red en Enfermedades Neurodegeneratives, “Centres for Networked Biomedical Research into Neurodegenerative Diseases”), to which Fundació ACE is associated. Fundació ACE also participates actively in other international initiatives, such as IGAP (International Genomics of Alzheimer’s Project) and Belgium’s Early Onset Dementia Consortium.

Centro Investigación Biomédica en Red Enfermedades Neurodegenerativas (CIBERNED)

In the final quarter of 2012, Fundació ACE and the CIBERNED, supported by the Institute of Health Carlos III and the Ministry of Economy and Competitiveness, signed a collaboration agreement to promote and develop studies, activities and research in the field of neurodegenerative diseases.

The purpose of agreement, whose duration is indefinite, is to promote and collaborate in scientific research of the problems related to neurodegenerative diseases, the development of knowledge and its integration into society. In addition, one of the priority aims of the partnership is to develop research groups at the highest international level to investigate the mechanisms of neurodegeneration.

Centre de Regulació Genòmica (CRG)

On 15 March 2012, a collaboration agreement was signed between Fundació ACE and the CGR in Barcelona to carry out genetic studies into dementia and ageing. The agreement, initially to last two years, is intended to encourage collaboration between the two research centres, especially as regards specific scientific collaborations in the field of genomics and functional studies into cases of neurodegenerative diseases. The experience of the two research centres will serve to deepen understanding of these diseases from several points of view.

The agreement, whose initial duration is two years, is intended to encourage collaboration between these two research centres. Specifically, the two centres hope to collaborate on concrete projects in the field of genomics and on functional studies into cases of neurodegenerative diseases.

Wadsworth centre of the New York Department of Health

Fundació ACE. Instituto Catalán de Neurociències Aplicadas and the Wadsworth centre of the New York Department of Health have a collaboration agreement in Alzheimer’s and Parkinson’s disease research.

The research is focused on the study of the effect on neurological diseases of the major histocompatibility complex, a family of genes located on chromosome 6. The main interest of the partnership is gene–gene and gene–environment interactions in the pathologies of Alzheimer’s and Parkinson’s disease.

Dr Agustín Ruiz, chief researcher at Fundació ACE, and Dr Haydeh Payami of the Wadsworth centre and the lead investigators directing the joint research.

In addition, both parties to the agreement are committed to exchanging monthly summaries of their advances. The collaboration period is set to last until 31 March 2018.

The Wadsworth centre of the New York Department of Health is a public health research centre, established in 1901.

Global Alzheimer’s Association Interactive Network (GAAIN)

Fundació ACE is a member of the Global Alzheimer’s Association Interactive Network.

The Global Alzheimer’s Association Interactive Network (GAAIN) is a big data community for cohort discovery and data exploration that promotes data sharing among a federated, global network of data partners who are studying Alzheimer’s disease and other dementias. It is a collaborative project that provides researchers around the globe access to clinical, genetic, and imaging data on Alzheimer’s disease from hundreds of thousands of subject participants through compelling and intuitive graphical user interfaces.

Led by Dr. Arthur Toga, Director of the Laboratory of Neuro Imaging (LONI) at the University of Southern California, GAAIN’s goal is to transform the way researchers work together to answer fundamental questions related to understanding the causes, diagnosis, treatment, and prevention of Alzheimer’s disease. To learn more and use GAAIN, visit